Harebrained Schemes, the developer of the Shadowrun trilogy, BATTLETECH and The Lamplighters League, has announced that it will part ways with its publisher Paradox Interactive on January 1, 2024. The decision was made by mutual agreement, following the disappointing launch of their latest game, a turn-based strategy game set in a steampunk Victorian era.
Paradox Interactive acquired Harebrained Schemes in 2018, hoping to expand its portfolio of strategy and management games. However, the two companies had different creative and strategic visions, and The Lamplighters League failed to meet their expectations. Paradox will retain the ownership of the game and other titles developed by Harebrained Schemes, while Harebrained Schemes will seek new opportunities with other partners.
“Paradox has refocused its strategy towards its core niches within strategy and management games with endless qualities,” said Charlotta Nilsson, COO of Paradox. “We and HBS’ leadership have been discussing what would happen after the release of The Lamplighters League, but a new project or sequel in the same genre was not in line with our portfolio plans. Hence, we believe that a separation would be the best way forward. We’re very happy that this talented, gifted studio has the chance to continue and can’t wait to see what they will make next.”
“Harebrained Schemes will support The Lamplighters League through the end of the year while we seek funding and partnerships for an independent future in 2024," said Brian Poel, Studio Operations Manager of HBS. “Our studio mission remains the same: to make games that challenge your mind and touch your heart.”
The Lamplighters League is a game that lets you lead a secret society of inventors and adventurers in a Victorian London plagued by supernatural threats. You have to manage your resources, recruit new members, research new technologies, and fight against rival factions and monsters. The game was released on September 21st, 2023, on Steam, and has received mixed reviews from the players.
Comments
Post a Comment